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A B S T R A C T
Background: We examined NK cell phenotypes and functions after seven years of ART and undetectable viral
loads (< 50 copies/ml) with restored CD4 T-cell counts (≥500 cells/μl) and age-matched healthy-HIV-unin-
fected individuals from the same community.
Methods: Using ﬂow-cytometry, NK cell phenotypes were described using lineage markers (CD56+/-CD16+/−).
NK cell activation was determined by expression of activation receptors (NKG2D, NKp44 and NKp46) and ac-
tivation marker CD69. NK cell function was determined by CD107a, granzyme-b, and IFN-gamma production.
Results: CD56 dim and CD56 bright NK cells were lower among ART-treated-HIV-infected than among age-
matched-HIV-negative individuals; p= 0.0016 and p=0.05 respectively. Production of CD107a (P= 0.004)
and Granzyme-B (P= 0.005) was lower among ART-treated-HIV-infected relative to the healthy-HIV-uninfected
individuals. NKG2D and NKp46 were lower, while CD69 expression was higher among ART-treated-HIV-infected
than healthy-HIV-uninfected individuals.
Conclusion: NK cell activation and dysfunction persisted despite seven years of suppressive ART with “nor-
malization” of peripheral CD4 counts.
1. Introduction
Natural killer (NK) cells have exceptional roles in host immune re-
sponse to infection including bridging the gap between the innate and
adaptive immune systems [1], recognizing and killing virally infected
cells, as well as recognizing and clearing cancerous and stressed cells
[2,3]. Diﬀerent infections alter the NK cell compartment, for example,
unique NK cell signatures have been primed by Cytomegalovirus (CMV)
and Varicella zoster viruses [4,5]. Insights into recent work have fur-
ther highlighted the ability of NK cells to have memory like phenotypes
to diﬀerent viral infections [6,7].
HIV infection is associated with several changes in the NK cell
compartment, including phenotypic and functional abnormalities that
contribute to diﬃculty in the control of HIV progression [8]. Upon HIV
infection, NK cells rapidly divide and produce huge amounts of IFN-γ
cytokine as a way of controlling the infection [9]. Strong NK cell ac-
tivity and cytotoxic receptor expression are associated with preserva-
tion of CD4 T-cells and lower viral set point [10]. ART was shown to
restore NK cell numbers with a mature phenotype in HIV-infected in-
dividuals although NK cell phenotypes and the ability to produce IFN-ɣ
and cytotoxicity remained impaired after one year of ART [11–13]. We
previously demonstrated persistence of the pro-inﬂammatory subset of
NK cells (CD56++ CD16+), after four years of successful ART with
viral suppression [14]. Moreover, persistent pro-inﬂammatory subsets
were associated with suboptimal CD4 count recovery [14].
NK cells have been shown to kill Mtb-infected cells directly or
through antibody-dependent cellular cytotoxicity (ADCC) [15], and
confer protection against Mtb infection as was shown in mice with T-
cell deﬁciencies [16]. Longitudinal studies among healthy individuals
in South Africa have shown that NK cell mediated cytotoxicity remains
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key to successful immune control of Mycobacterium tuberculosis infec-
tion, therefore peripheral NK cell phenotypes and function may inform
disease progression and treatment responses [17]. Our earlier studies
on NK cell phenotypes after four years of ART did not examine NK cell
function recovery. We postulate that NK cell function may take more
than four years of ART to recover to levels comparable to healthy HIV-
uninfected individuals, particularly among patients that initiated ART
at CD4 counts below 350 cells/μl. There is paucity of data on recovery
of NK cell function, among other innate immune dysfunctions asso-
ciated with HIV disease, particularly in Africa where other co-infections
like tuberculosis, and CMV remain endemic. We hypothesized that in-
nate immune dysfunction, for example, NK cell dysfunction may not
recover fully during ART, thereby aﬀecting recovery of adaptive T-cell
responses. Incomplete recovery of NK cell repertoire could contribute to
the persistent T-cell function abnormalities previously described in our
cohort of ART-treated adults, even when CD4 counts were restored to
levels above 500 cells/μl [18]. With emerging evidence that NK cell
function is key to protection against progression from latent Mtb in-
fections to active tuberculosis, understanding recovery of NK cell
function during ART is essential to the control of Mtb infection among
ART-treated HIV-infected adults in sub-Saharan Africa where Tb re-
mains a leading opportunistic infection and a leading cause of death
[19,20].
This paper therefore, describes the NK cell phenotypes and function
among individuals with successful HIV treatment, viral suppression and
CD4 counts above 500 cells/μl after seven years of therapy within an
African cohort. In addition to the distribution of NK cell phenotypes, we
describe the expression of NK activating receptors NKG2D, NKp46 and
NKp44, cytokine production, as well as their cytotoxic functions as
expressed by CD107a and Granzyme b production. Our results provide
insight on recovery of the innate immune system among HIV-infected
adults after long-term ART and the potentially associated risk of active
tuberculosis and common viral infections. Our comparisons between
ART-treated individuals that have attained otherwise normal CD4
counts with age-matched HIV-uninfected individuals from the same
community, provide clinicians with contextual data on persistent host
susceptibility to common infections. This will inform potential inter-
ventions geared towards optimisation of immune recovery of the HIV-
infected adults on life-long ART in sub-Saharan Africa.
2. Materials and methods
2.1. Study design and participants
It was a comparative cross-sectional study which utilised cryopre-
served PBMCs of all the 30 optimal responders to ART, deﬁned as HIV-
infected ART-treated adults who had attained a CD4 T-cell count
≥500 cells/μl after seven years of suppressive ART within the
Infectious Diseases Institute (IDI) HIV treatment research cohort lo-
cated at Mulago National referral hospital.
2.2. Cohort description
In April of 2004 and April 2005, the IDI HIV treatment research
cohort was founded, enrolling and initiating a total of 559 consecutive
ART-naïve HIV-infected patients. HIV treatment drugs were oﬀered by
the Global Fund (a generic combined formulation of stavudine [d4T],
lamivudine [3TC], and nevirapine [NVP] and the US President's
Emergency Plan for AIDS Relief (a combined formulation of zidovudine
[ZDV] and 3TC plus efavirenz [EFZ] or NVP). Tenofovir [TDF] was
given as the drug of choice to patients that had toxicities to ZDV.
Cotrimoxazole prophylaxis was given to all people living with HIV in
accordance to the national guidelines at the time. Group counselling
sessions were carried out at least three times to support adherence to
ART. Patients returned to the clinic monthly for physician's review of
adherence to medication, toxicities, and acute infections. HIV RNA viral
loads, complete blood counts and CD4 lymphocyte counts were mea-
sured 6 monthly [21]. Optimal responders, consecutively enrolled into
this immune recovery study, were individuals in the highest quartile of
CD4 increase (a quartile with mean CD4 increase of 823 cells/μl) who
did not have any opportunistic infection in the six months preceding
immune recovery study [18]. These were compared with 30 age-mat-
ched HIV-uninfected adults within the communities served by Mulago
National referral hospital routine HIV testing program. These were
healthy asymptomatic individuals that had negative HIV test results
within the routine HIV testing program.
2.3. Ethical considerations
Ethical approval of the study was sought from the institutional re-
view board of School of Biomedical Sciences Makerere University
College of Health Sciences. All participants provided written informed
consent.
2.4. Monoclonal antibodies and ﬂow cytometric analysis
The following ﬂuorochrome-conjugated antibodies were used in this
study: CD3 BV510, CD14 BV510, CD19 BV510, CD56 PE, CD16 PECY7,
CD38 BV605, NKG2D PERCPCY5.5, NKp44 PE-CY7, NKp46 BV450,
CD107a APC, CD8 APC CY7, CD69 BV785, HLADR BV711 for surface
antigens; GRANZYME B Paciﬁc Blue and IFN-γ BV488 for intracellular
staining. Cryopreserved PBMC from ART-treated HIV-infected in-
dividuals and age-matched healthy HIV-negative adults from the same
community were snap thawed and washed in pre-warmed complete
Roswell Park Memorial Institute (cRPMI) 1640 medium supplemented
with 10% fetal bovine serum (FBS). The cells were rested for 4 h in 5ml
of R10 at 37 °C in a 5% CO2 incubator. After resting, cells were washed
with R10 and the numbers of viable cells were counted. Surface staining
was done at 4 °C for 30min with saturating concentrations of diﬀerent
combinations of antibodies in the presence of ﬁxable live/dead stain
(Invitrogen). Cells were then ﬁxed and acquired using the LSRII ﬂow
cytometer (BD Bioscience FACSDiva8.0) and data analysed using
FlowJo software (Tree Star, Version 10.1). Natural Killer cells were
distinguished by their surface receptor expression of CD56+/− and the
CD16+/− (Fig. 1). The subsets were assessed according to the intensity
of expression of the CD56 marker; CD56+ as the dim NK cells and
CD56++ as the bright NK cells. CD3 expression was used to exclude T
cells, CD19 for the exclusion of B cells and CD14 was used to exclude
the monocytes. Fluorescence minus one controls (FMOs) were applied
to standardise the gating and compensation controls to correct for
spectral overlap. At least 100,000 events of CD56+CD16+ were ac-
quired and analysed (Fig. 1). Comparisons and pictures were made
using Graph Prism 6. The Mann Whitney test for non-parametric vari-
ables was used to compare proportions of the diﬀerent cell subsets and
their functions among the two groups. A signiﬁcant diﬀerence was
obtained with p values < 0.05.
2.5. Titration of NK cell stimulation
In our optimisation experiment we added 2×106 PBMCs to the
unstimulated well, [K562 alone (5:1 ratio)], [K562 (5:1 ratio) and IL-2
(100 IU/ml)], [K562 (5:1ratio), IL-2(100 IU/ml) and IL-12 (50 ng/ml)],
[K562(5:1ratio), IL-2(100 IU/ml) and IL-15 (100 ng/ml)] and ﬁnally
[K562(5:1ratio), IL-12 (50 ng/ml) and IL-15 (100 ng/ml)]. From our
analysis, the combination of [K562 (5,1ratio), IL-12 (50 ng/ml) and IL-
15 (100 ng/ml)] was the best because it consistently gave the highest
percentage of granzyme B production, CD107a, IFN-gamma and total
NK cells numbers (Fig. 2).
2.6. NK cell functional assays
PBMC were incubated with MHC-devoid K562 cells (5:1 ratio) in
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combination with IL-12 (50 ng/ml) and IL-15 (100 ng/ml) recombinant
proteins for 6 h at 37 °C in the presence of CD107a- APC antibody (BD
Biosciences). To determine interferon gamma production, we added
Monensin, 1/1500 concentration, Brefeldin A 1/250 concentration –
(BD Biosciences) to each of the above wells and these were incubated
for 6 h at 37 °C with 5% CO2. An additional well containing PMA 50 ng/
mL, and ionomycin 1 μg/mL (catalogue No. P8139)- SIGMA) was used
as the positive control. At the end of the incubation, cells were washed
with BD Pharm staining buﬀer (Cat. No. 554656), ﬁxed and permea-
bilized to allow speciﬁc anti-cytokine ﬂuorescence antibody conjugates
to enter into the cell. Samples were acquired on an LSRII using BD FACS
Diva 8.0 sofware (BD Bioscience) and data analysed using FlowJo
software (Tree Star, Version 10.1). Fluorescence minus one controls
(FMOs) were applied to standardise the gating and compensation con-
trols to correct for spectral overlap.
3. Results
3.1. Disparities in the NK cell numbers and phenotype distribution in ART-
treated HIV-infected individuals
We assessed the NK cell phenotypes and functions from PBMC of
HIV-infected individuals that had been on ART for at least seven years
and these were compared with age-matched healthy HIV-uninfected
individuals from the same community. The HIV-infected individuals
had a nadir median CD4 count of 97 (11, 158) cells/μl at ART initiation
and a median CD4 count of 607 (759, 996) cells/μl with viral load <
50 copies/ml at enrolment in this study; denoted as Optimal Immune
responders. Of 30 ART-treated optimal responders, 26(87%) were fe-
male, median age was 40 IQR (38–46) years, BMI median was 22.57
IQR (20, 25), 93% were free from hypertension and 97% had no dia-
betes. Of the 30 healthy HIV-uninfected individuals, 63% (19/30) were
female, their median age was 36 IQR (33–42) years, median Body Mass
Index (BMI) 25.95(22, 30), 8% were hypertensive and 4% were dia-
betic. All participants had no fevers at the time of enrolment in the
Fig. 1. Gating strategy for Natural Killer (NK) cell phenotypes and function markers (CD107a, Granzyme B and Interferon gamma (IFN-G).
Fig. 2. Optimisation of Natural Killer (NK) cell stimulation. PBMCs were cultured with medium alone or with combinations of diﬀerent stimulants (K562, IL-2, IL-12
and IL-15) for 6 h. A shows percentage of Granzyme B production, B shows percentage IFN-gamma production and C shows percentage expression of CD107a.
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study [18].
3.1.1. NK cell phenotypes
Percentages of the CD56+ (CD56dim) NK cells were signiﬁcantly
lower (P= 0.0016) in ART-treated HIV-infected individuals than in
healthy HIV-uninfected individuals despite having a CD4 count of>
500 cells/μl after seven years of ART. Similarly, proportions of CD56+
+ (CD56 bright) NK cells were signiﬁcantly lower (P=0.05) in ART-
treated individuals than in healthy HIV-uninfected individuals (Fig. 3).
Total NK cell numbers (CD56+ CD16+/−) and the CD56- phenotype
were comparable among the two groups; P= 0.397 and P= 0.117.
3.1.2. NK cell receptor expression
Of the total NK cell phenotypes, the percentage expressing the
natural cytotoxic receptor NKP46 was signiﬁcantly lower in ART-
treated HIV-infected individuals than among the healthy HIV-unin-
fected adults; P= 0.015. Also, the c-type lectin receptor NKG2D was
found to be signiﬁcantly lower in the ART-treated individuals than in
their HIV-uninfected counterparts; P= 0.0001 (Fig. 4). Expression of
the NKP44 natural cytotoxic receptor was signiﬁcantly higher among
the ART-treated HIV-infected individuals than in the HIV-uninfected
individuals; P= 0.014 (Fig. 4).
3.2. NK cell functions of cytolysis, degranulation and interferon gamma
production
The NK cytolytic and degranulation function was assessed by mea-
suring the levels of granzyme b production and the expressions of the
CD107a. The cytolytic CD56dim NK cells produced signiﬁcantly lower
levels of Granzyme B in ART-treated HIV-infected adults than their age-
matched healthy HIV-uninfected counterparts; P= 0.004. Furthermore,
the levels of CD107a expression were signiﬁcantly lower in the ART-
treated adults with CD4 > 500 cells/μl after seven years of ART, re-
lative to their age-matched HIV-uninfected counterparts; P= 0.005
(Fig. 5).
4. Expression of activation markers in NK cell phenotypes
NK cells recent activation status, as denoted by CD69 expression,
was evaluated on the Total NK cells (CD56+ CD16+/−), CD56dim NK
cells (CD56+ CD16+) and CD56bright NK cells CD56++CD16−).
Recent activation status of the entire pool of circulating NK cells was
signiﬁcantly higher in ART-treated HIV-infected individuals than in
healthy HIV-uninfected individuals despite having a CD4 count of >
500 cells/μl and seven years of ART; Total NK cells (P=0.008),
CD56dim (P=0.01) and CD56 bright (P= 0.0015), as shown in Fig. 6.
Although the dysfunctional CD56- population were comparable both in
the HIV-infected and HIV-uninfected population, the expression of
CD69 was higher in the HIV-infected than in the HIV-uninfected po-
pulation (P= 0.0015), Fig. 6.
5. Discussion
We examined populations of circulating NK cell phenotypes, re-
ceptor expression and functions of cytotoxicity and cytokine production
among HIV-infected individuals after seven years of suppressive ART.
This cross-sectional study demonstrated the persistent perturbations in
NK cell phenotypes and functions among patients that restored per-
ipheral CD4 T-cells to> 500 cells/μl in a Ugandan cohort. These ﬁnd-
ings could mirror the outcomes of long term ART treatment in diﬀerent
Sub-Saharan cohorts where individuals started ART with nadir CD4
counts below 350 cells/μl.
We observed signiﬁcantly lower proportions of the cytolytic
CD56dim (CD56+) and cytokine producing CD56bright (CD56++) NK
cells in the HIV-infected individuals relative to age-matched HIV-un-
infected individuals. NK cells are known to work eﬃciently in the
clearance of viruses and tumor forming cells [22]. Therefore, few cy-
tolytic and Interferon gamma producing NK cells would imply persis-
tent risk of succumbing to viral infections and cancers of viral origin.
Similarly the aﬀected ART-treated adults may not have suﬃcient NK
cell response to control replication of residual HIV-1 virus. The lack of
control of the residual HIV virus likely contributes to the ongoing NK
cell activation status in ART-treated HIV-infected adults we observed.
In Spain, Frias et al. observed similar ﬁnding of lower CD56dim NK
cells in the HIV-infected individuals than in HIV-uninfected healthy
donors even after approximately eight years of ART with undetectable
viral load and CD4 T-cell count> 500 cells/μl [23]. Similarly, Alter
et al. observed an early depletion of CD56 bright NK cell subset during
acute HIV infection followed by a continual reduction in the CD56 dim
NK cells subset after one year of infection, which did not normalise to
levels in HIV-uninfected controls after six months of ART [24]. After
15 years of ART, in South Carolina –USA, Luo et al. reported similar NK
cell phenotype distribution among ART-treated and HIV-uninfected
individuals [25]. It is therefore likely that with longer durations of ef-
fective ART, the NK cell compartment may recover to levels comparable
with HIV-uninfected individuals. A better understanding of the mag-
nitude of perturbations of the NK cells in the reticuloendothelial system
may provide more insight on what is required to design more eﬀective
therapeutic strategies to optimize immune recovery.
We also found that expression of activating natural cytotoxic re-
ceptors of NKP46 and NKG2D was higher among HIV-infected adults.
NKp46, however, was lower among ART-treated HIV-infected adults
relative to their age-matched HIV-negative counterparts. NKp44 re-
ceptor, highly expressed on recently activated NK cells [26], was higher
Fig. 3. Phenotypic evaluation of Natural Killer (NK) cells among HIV-infected
individuals with CD4 T-cells≥ 500 cells/μl after seven years of ART relative to
age-matched healthy HIV-negative individuals from the same community.
CD56+CD16+/− represents the CD56 dim NK cells, CD56++CD16- re-
presents CD56 bright NK cells and CD56-CD16+ represents CD56 negative NK
cells. The Mann–Whitney U test for non-parametric tests was used for com-
parisons of the two groups with statistical signiﬁcance at p values≤ 0.05.
Fig. 4. Evaluation of Natural Killer (NK) cell receptor expression for NKG2D,
NKp46 and NKp44 among HIV-infected individuals with CD4 T cells≥5 00
after seven years of ART and their age-matched healthy HIV-negative coun-
terparts.
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among the ART-treated HIV-infected adults; implying persistent acti-
vation of the NK cell pool despite seven years of eﬀective ART. Simi-
larly, CD69, a marker for recent NK cell activation was high in the HIV-
infected relative to HIV-uninfected individuals. Persistently high levels
of NK cell activation, as measured by CD69, were signiﬁcantly higher in
the HIV positive individuals compared to the HIV-negative individuals
after an average of three years of ART [27]. NK cells expressing NKp46
carry out an important role of NK cell cytotoxicity against tumor cells
and virally infected cells. Eﬀective NK cell cytolytic function requires
delicate balance between the activating and inhibitory receptors [8].
Downregulation of the receptors during chronic HIV infection has been
associated with risk of development non-AIDS-deﬁning cancers [28,29].
Low NKp46 receptor expression was previously reported after three
years of HIV treatment in a European cohort, where it improved with
increasing duration of ART [23]. Persistent immune activation has been
associated with development of non-AIDs illnesses which are emerging
as major causes of death in adults aging with HIV [30,31]. The ongoing
immune activation despite eﬀective ART and a CD4 > 500 cells/μl is
not fully explained. We postulate that it may be driven by residual viral
replication lymph nodes and other tissues.
We further assessed NK cell function following stimulation of NK
cells with MHC- devoid K562 cells, IL-12 and IL-15 recombinant pro-
teins. We measured the expression of CD107a, a molecule found within
membrane-bound lytic lysosomal vesicles encompassing proteins such
as granzyme and perforin. CD107a is a known functional marker for NK
cell cytolytic activity upon cell stimulation [32]. We observed sig-
niﬁcantly lower cytolytic activity of NK cells as measured by granzyme
B production and CD107a in the ART-treated HIV-infected individuals
than in their HIV-uninfected counterparts despite the seven years of
eﬀective ART. Alter et al. also observed high levels of CD107a in HIV-
infected viremic individuals, which recovered after six months of ART
[33]. Our Ugandan cohort started ART when they were critically ill
with a nadir CD4 count of< 200 cell/μl a state in which the whole
repertoire of the immune system had been severely compromised. We
postulate that the status of the immune system at the point of ART
initiation has an eﬀect on the recovery of the NK cell CD107a function
and granzyme B production. More so, the eﬀects of persistent immune
activation a phenomenon that has been observed in this group of pa-
tients, can further compromise NK cell functional recovery despite the
seven years of ART. Production of IFN-gamma, after stimulation with
an extra NK-tropic cytokine IL-15, IL-12 and K562, was lower in the
HIV-infected than HIV-uninfected individuals. Inability to restore NK
cell interferon gamma production despite the presence of CD161+/
CD56+ mature NK cells in pro- portions was previously reported [11].
Further studies looking at the NK cell gene signatures among the HIV-
infected individuals may provide a better understanding of the biolo-
gical pathways that remain deranged during ART in sub-Saharan Africa.
Recent data from South African HIV-negative cohorts showed that
the cohorts' NK cells decreased during progression from latent infection
to active disease, and enhanced NK cell cytotoxic responses were as-
sociated successful immune control of Mtb infection as evidenced by
maintenance latent tuberculosis status [17]. In mouse models with T-
cell deﬁciencies, NK cells conferred protection against Mtb infection
[16]. Therefore persistent NK cell activation and dysfunction observed
among ART-treated adults in sub-Saharan Africa, where Mycobacterium
tuberculosis infection is endemic, presents a potential mechanism for the
persistently high levels of active tuberculosis in our HIV treatment co-
hort [20,34].
Noteworthy, majority of the ART-treated adults with CD4
counts≥ 500 cells/ul in this study were female, which reﬂects the sub-
Saharan HIV epidemic where women are disproportionately more af-
fected than men. In our previous analysis of immune recovery among
Fig. 5. Natural Killer (NK) cell function among ART-treated HIV-infected individuals with CD4 T-cells≥ 500 cells/μl after seven years of ART relative to age-matched
healthy HIV-negative individuals. A shows proportion of NK cells expressing CD107a, B shows proportion of NK cells producing interferon gamma, and C shows
proportion of NK cells producing Granzyme B. The Mann–Whitney U test for non-parametric tests was used to compare the two groups with statistical signiﬁcance at
p values ≤0.05.
Fig. 6. CD69 expression on the NK cell subsets. A shows the proportion of CD56dim NK cells expressing CD69, B shows the proportion of CD56 bright NK cells
expressing CD69, and C shows the proportion of CD56 negative NK cells expressing CD69. The boxes and whiskers represent medians, 5th and 95th percentiles. The
Mann–Whitney U test for non-parametric tests was used to compare ART-treated HIV-infected and healthy HIV-uninfected individuals, with statistical signiﬁcance at
p values ≤0.05.
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ART-treated adults in Uganda, Kenya, and Tanzania over 65% of HIV-
treated individuals were female although there was no statistical dif-
ference in gender among ART-treated adults with CD4 counts above
and below 500 cells/μl after ﬁve years of treatment [34,35], yet CD4
counts in the general healthy the Ugandan population tend to be higher
in women than men [36]. However diﬀerences in NK cell phenotypes
among healthy HIV-negative men and women are yet to be studied.
6. Conclusions
Persistent NK cell activation, low cytolytic activity and low cytokine
production were observed after seven years of suppressive ART. It is
likely that ART-treated HIV-infected individuals remain susceptible to
opportunistic infections and malignancies of viral origin. A better un-
derstanding of the biological pathways driving the NK cell dysfunction
would inform development of novel adjunctive therapies to improve
recovery and long term health outcomes of HIV treatment.
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